Pacira BioSciences
PCRX
185 hedge funds and large institutions have $1.91B invested in Pacira BioSciences in 2017 Q4 according to their latest regulatory filings, with 36 funds opening new positions, 76 increasing their positions, 52 reducing their positions, and 30 closing their positions.
81% more call options, than puts
Call options by funds: $26.7M | Put options by funds: $14.8M
46% more repeat investments, than reductions
Existing positions increased: 76 | Existing positions reduced: 52
20% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 30
16% more capital invested
Capital invested by funds: $1.64B → $1.91B (+$268M)
3% more funds holding
Funds holding: 180 → 185 (+5)
5.17% less ownership
Funds ownership: 108.44% → 103.26% (-5.2%)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$21.4M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
+$15.1M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
+$12.4M |
| 4 |
CCM
Consonance Capital Management
New York
|
+$8.81M |
| 5 |
HM
HealthCor Management
New York
|
+$8.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WRF
Waddell & Reed Financial
Overland Park,
Kansas
|
-$30.6M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$23.1M |
| 3 |
ACA
Avoro Capital Advisors
New York
|
-$18.3M |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$15.6M |
| 5 |
SI
Standard Investments
New York
|
-$15M |
PCRX Hedge Fund Activity: Q4 2017 in Review
185 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Pacira BioSciences (PCRX) for Q4 2017, worth a combined $1.91B — up 16% from $1.64B a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new PCRX positions and 30 closed out — a net gain of 6 holders — while 76 added to existing stakes and 52 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $21.4M. The largest seller was Waddell & Reed Financial, exiting entirely with an estimated $30.6M sold.
- 185 institutional investors held Pacira BioSciences (PCRX) as of Q4 2017, up from 180 in Q3 2017.
- Funds reported $1.91B of Pacira BioSciences stock for Q4 2017, up 16% quarter-over-quarter.
- 36 funds opened new Pacira BioSciences positions in Q4 2017 and 30 closed out, a net change of +6 holders.
- The largest Pacira BioSciences buyer in Q4 2017 was Millennium Management, an estimated $21.4M added.
- The largest Pacira BioSciences seller in Q4 2017 was Waddell & Reed Financial, an estimated $30.6M sold.
Based on aggregated 13F filings for Q4 2017.